Product
Glasdegib
Aliases
PF04449913, PF 04449913, PF-04449913
Name
Daurismo
INN Name
glasdegib
FDA Approved
Yes
6 clinical trials
1 organization
9 indications
1 document
Indication
Myelodysplastic SyndromeIndication
Chronic Myelomonocytic LeukemiaIndication
Acute Myeloid LeukemiaIndication
Soft Tissue SarcomaIndication
Recurrent Acute Myeloid LeukemiaIndication
Chronic Graft Versus Host DiseaseIndication
FasciitisClinical trial
A MULTI-CENTER CONTINUATION STUDY EVALUATING AZACITIDINE WITH OR WITHOUT GLASDEGIB (PF-04449913) IN PATIENTS WITH PREVIOUSLY UNTREATED ACUTE MYELOID LEUKEMIA, MYELODYSPLASTIC SYNDROME OR CHRONIC MYELOMONOCYTIC LEUKEMIAStatus: Completed, Estimated PCD: 2022-12-02
Clinical trial
Phase 3 Study to Assess Gemtuzumab, in Combination With Standard Chemotherapy, on MRD Levels, and the Role of Glasdegib as a Post-transplant Maintenance, in Adult, 18-60 Years, With Previously Untreated de Novo Fav-interm Risk AMLStatus: Recruiting, Estimated PCD: 2024-04-01
Clinical trial
Molecular Profiling of Advanced Soft-tissue Sarcomas. A Phase III StudyStatus: Active (not recruiting), Estimated PCD: 2023-12-01
Clinical trial
Phase II Study of the Combination of CPX-351 and Glasdegib in Previously Untreated Patients With Acute Myelogenous Leukemia With MDS Related Changes or Therapy-related Acute Myeloid LeukemiaStatus: Recruiting, Estimated PCD: 2024-06-01
Clinical trial
An Open-Label Phase Ib/II Multi-Arm Study of OX40 Agonist Monoclonal Antibody (mAb), Anti-PDL1 mAb, Smoothened Inhibitor, Anti-CD33 mAb, Bcl-2 Inhibitor and Azacitidine as Single-Agents and/or Combinations for the Treatment of Patients With Acute Myeloid Leukemia (AML)Status: Completed, Estimated PCD: 2022-02-04
Clinical trial
A Single-Arm, Open-Label, Phase I/II Study of Glasdegib for Sclerotic Chronic Graft-Vs-Host DiseaseStatus: Terminated, Estimated PCD: 2023-08-23
Document
DailyMed Label: DaurismoOrganization
Pfizer Laboratories Div Pfizer Inc